glp 1 drugs medicaid More states consider dropping GLP-1 weight loss from • Stateline As demand for weight-loss drugs

In the STEP 1 trial, approximately 3840% of total weight lost during semaglutide treatment came from lean mass

The average cost of employer-sponsored health insurance reached nearly $17,500 per employee last year, according to a national survey released in November by business consultant Mercer

2 Digital care and dosing for GLP-1 therapy One of the most promising innovations in obesity management is the integration of digital coaching with flexible medication dosing

Development and validation of a new score to assess the risk of posttransplantation diabetes mellitus in kidney transplant recipients

It has been proposed that androgen excess may be a risk factor in women with IIH, independent of obesity, and that hyperandrogenism may play a pathophysiological role in disease onset

Nothing to be concerned about it seems